SRRM2 and Miyoshi myopathy: The consistency between plasma cell SRRM2 expression and mSMART 3.0 risk stratification and cytogenetic abnormalities suggests that plasma cell SRRM2 expression could even serve as a good indicator for MM risk stratification.